Ken Okamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ken Okamura has a total of 309 co-authors. Here are the top co-authors by number of shared publications:
Tamio Suzuki
Department of Dermatology, Faculty of Medicine Yamagata University Yamagata Japan
41 shared publicationsYutaka Hozumi
Department of Dermatology, Faculty of Medicine Yamagata University Yamagata Japan
28 shared publications- Yuko Abe
Department of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan
21 shared publications - Yuta Araki
Department of Dermatology Faculty of Medicine Yamagata University Yamagata Japan
12 shared publications - Masahiro Hayashi
Department of Dermatology, Faculty of Medicine Yamagata University Yamagata Japan
11 shared publications - Toru Saito
Department of Dermatology, Faculty of Medicine Yamagata University Yamagata Japan
11 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wiley in The Journal of Dermatology
Clinical and Patient‐Reported Factors Associated With Impaired Quality of Life in Japanese Patients With Vitiligo: A Multicenter Questionnaire Study Using VitiQoL
Vitiligo can cause a substantial psychosocial burden. However, the clinical and patient‐reported features associated with impaired disease‐specific quality of life (QoL) in Japanese patients remain incompletely characterized. We conducted a multicenter, cross‐sectional questionnaire study to examine the associations between the Vitiligo‐specific Quality‐of‐Life (VitiQoL) instrument and clinical variables reported by patients and physicians. A total of 255 questionnaires were collected, and 227 patients with complete VitiQoL data were included in the main analysis. The mean VitiQoL total score was 40.6 ± 22.4. Higher VitiQoL scores were associated with female sex, exposed‐site involvement, and border hyperpigmentation, with scores increasing progressively with the number of involved exposed regions. VitiQoL scores showed a trend toward an inverse correlation with age. Lesion‐associated symptoms were also associated with higher VitiQoL scores, whereas non‐lesional skin symptoms were not. Lesion‐associated symptoms were associated with physician‐rated disease severity. Treatment response assessed by either patients or physicians was not associated with VitiQoL scores. In multivariable analysis, female sex, younger age, a greater number of exposed regions, and border hyperpigmentation were independently associated with higher VitiQoL scores, whereas physician‐rated disease severity and lesion‐associated symptoms were not. These findings highlight the multifactorial nature of QoL impairment in vitiligo and the importance of incorporating both clinical and patient‐reported features into the assessment of QoL beyond repigmentation‐based treatment response.
- 18 September 2026
- Published by Wiley in The Journal of Dermatology
Open AccessClinical and Patient‐Reported Factors Associated With Impaired Quality of Life in Japanese Patients With Vitiligo: A Multicenter Questionnaire Study Using VitiQoL
Vitiligo can cause a substantial psychosocial burden. However, the clinical and patient‐reported features associated with impaired disease‐specific quality of life (QoL) in Japanese patients remain incompletely characterized. We conducted a multicenter, cross‐sectional questionnaire study to examine the associations between the Vitiligo‐specific Quality‐of‐Life (VitiQoL) instrument and clinical variables reported by patients and physicians. A total of 255 questionnaires were collected, and 227 patients with complete VitiQoL data were included in the main analysis. The mean VitiQoL total score was 40.6 ± 22.4. Higher VitiQoL scores were associated with female sex, exposed‐site involvement, and border hyperpigmentation, with scores increasing progressively with the number of involved exposed regions. VitiQoL scores showed a trend toward an inverse correlation with age. Lesion‐associated symptoms were also associated with higher VitiQoL scores, whereas non‐lesional skin symptoms were not. Lesion‐associated symptoms were associated with physician‐rated disease severity. Treatment response assessed by either patients or physicians was not associated with VitiQoL scores. In multivariable analysis, female sex, younger age, a greater number of exposed regions, and border hyperpigmentation were independently associated with higher VitiQoL scores, whereas physician‐rated disease severity and lesion‐associated symptoms were not. These findings highlight the multifactorial nature of QoL impairment in vitiligo and the importance of incorporating both clinical and patient‐reported features into the assessment of QoL beyond repigmentation‐based treatment response.
- 31 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8)
Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025)
Vitiligo is a common acquired hypopigmented disorder characterized by melanocyte damage and/or loss, primarily resulting from excessive oxidative stress and dysregulated immune responses targeting melanocytes. The initial guidelines for the diagnosis and treatment of vitiligo in Japan were published in Japanese in 2012 and in English in 2013 to provide clinical evidence for vitiligo management. Since then, there has been a substantial accumulation of pathological research and therapeutic evidence. The second guidelines for the diagnosis and treatment of vitiligo in Japan (2025) are presented as an updated resource for clinicians, incorporating worldwide expert recommendations and recent advances in basic and clinical research. These guidelines aim to provide updated knowledge for individuals with vitiligo, public health professionals, scientists, and dermatologists.
- 31 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8)
Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025)
Vitiligo is a common acquired hypopigmented disorder characterized by melanocyte damage and/or loss, primarily resulting from excessive oxidative stress and dysregulated immune responses targeting melanocytes. The initial guidelines for the diagnosis and treatment of vitiligo in Japan were published in Japanese in 2012 and in English in 2013 to provide clinical evidence for vitiligo management. Since then, there has been a substantial accumulation of pathological research and therapeutic evidence. The second guidelines for the diagnosis and treatment of vitiligo in Japan (2025) are presented as an updated resource for clinicians, incorporating worldwide expert recommendations and recent advances in basic and clinical research. These guidelines aim to provide updated knowledge for individuals with vitiligo, public health professionals, scientists, and dermatologists.
- 29 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5)
Hermansky–Pudlak Syndrome Type 3 Complicated by Schizophrenia and Crohn's‐Like Colitis
- 29 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5)
Hermansky–Pudlak Syndrome Type 3 Complicated by Schizophrenia and Crohn's‐Like Colitis
- 25 November 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (6) , e70066
Updated Analysis of Albinism in Japan: 290 Families With Novel Pathological Variants
We present an updated analysis of albinism in Japan, encompassing both oculocutaneous albinism (OCA) and ocular albinism (OA), based on 290 families, which expands our previous study by 100 additional families. The overall frequency distribution of major subtypes remained consistent with our previous findings: OCA4 remains the most prevalent subtype (67 patients, 23.1%), followed by OCA1 (57 patients, 19.7%), Hermansky–Pudlak syndrome (HPS) 1 (35 patients, 12.1%), and OCA2 (30 patients, 10.3%). Notably, our expanded analysis identified patients with rare subtypes, including OCA3, OCA6, HPS2, HPS3, HPS5, and HPS6, as well as OA, further demonstrating the genetic diversity of albinism in the Japanese population. Through comprehensive genetic screening of the additional 100 families, we identified 17 patients harboring previously unreported pathological variants across multiple albinism subtypes. These findings expand the variant spectrum of albinism in Japan, provide valuable insights for genetic counseling, and underscore the critical importance of comprehensive clinical evaluation and long‐term multidisciplinary follow‐up for patients with albinism, particularly those with HPS subtypes.
- 25 November 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (6) , e70066
Updated Analysis of Albinism in Japan: 290 Families With Novel Pathological Variants
We present an updated analysis of albinism in Japan, encompassing both oculocutaneous albinism (OCA) and ocular albinism (OA), based on 290 families, which expands our previous study by 100 additional families. The overall frequency distribution of major subtypes remained consistent with our previous findings: OCA4 remains the most prevalent subtype (67 patients, 23.1%), followed by OCA1 (57 patients, 19.7%), Hermansky–Pudlak syndrome (HPS) 1 (35 patients, 12.1%), and OCA2 (30 patients, 10.3%). Notably, our expanded analysis identified patients with rare subtypes, including OCA3, OCA6, HPS2, HPS3, HPS5, and HPS6, as well as OA, further demonstrating the genetic diversity of albinism in the Japanese population. Through comprehensive genetic screening of the additional 100 families, we identified 17 patients harboring previously unreported pathological variants across multiple albinism subtypes. These findings expand the variant spectrum of albinism in Japan, provide valuable insights for genetic counseling, and underscore the critical importance of comprehensive clinical evaluation and long‐term multidisciplinary follow‐up for patients with albinism, particularly those with HPS subtypes.
- Open Access
- 23 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 169-179
Genetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations
Genetic pigmentary disorders represent a diverse group of genetic conditions characterized by alterations in melanin production and transport and melanocyte development, resulting from single‐gene pathological variants. These disorders encompass both hypopigmentary and hyperpigmentary phenotypes, affecting not only skin pigmentation but also ocular, auditory, and systemic manifestations. This review examines the molecular mechanisms underlying major genetic pigmentary disorders, including hypopigmentary (e.g., oculocutaneous albinism, piebaldism, and Waardenburg syndrome) and hyperpigmentary (e.g., dyschromatosis symmetrica hereditaria, dyschromatosis universalis hereditaria, reticulate acropigmentation of Kitamura, and Dowling–Degos disease) disorders. Additionally, we discuss RASopathies, in which pigmentary abnormalities occur alongside multisystem developmental anomalies. Comprehensive understanding of these conditions can provide crucial insights into melanocyte biology and guide future clinical management strategies for affected patients.
- 23 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 169-179
Open AccessGenetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations
Genetic pigmentary disorders represent a diverse group of genetic conditions characterized by alterations in melanin production and transport and melanocyte development, resulting from single‐gene pathological variants. These disorders encompass both hypopigmentary and hyperpigmentary phenotypes, affecting not only skin pigmentation but also ocular, auditory, and systemic manifestations. This review examines the molecular mechanisms underlying major genetic pigmentary disorders, including hypopigmentary (e.g., oculocutaneous albinism, piebaldism, and Waardenburg syndrome) and hyperpigmentary (e.g., dyschromatosis symmetrica hereditaria, dyschromatosis universalis hereditaria, reticulate acropigmentation of Kitamura, and Dowling–Degos disease) disorders. Additionally, we discuss RASopathies, in which pigmentary abnormalities occur alongside multisystem developmental anomalies. Comprehensive understanding of these conditions can provide crucial insights into melanocyte biology and guide future clinical management strategies for affected patients.
- 22 September 2025
- Published by Elsevier in Journal of Dermatological Science
- Vol. 120 (2) , 77-79
Deep intronic variant in TYR causes OCA1A in Japanese families through pseudoexon activation
- 22 September 2025
- Published by Elsevier in Journal of Dermatological Science
- Vol. 120 (2) , 77-79
Deep intronic variant in TYR causes OCA1A in Japanese families through pseudoexon activation
- 21 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (2) , 374-382.e4
A Hairless Mouse Model for Vitiligo: Enhancing Preclinical Therapeutic Evaluation
- 21 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (2) , 374-382.e4
A Hairless Mouse Model for Vitiligo: Enhancing Preclinical Therapeutic Evaluation
- Open Access
- 28 April 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6) , e430-e480
Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition
- 28 April 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6) , e430-e480
Open AccessWound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition
- 20 March 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6)
Hypopigmented malignant melanoma in a patient with oculocutaneous albinism type 4
- 20 March 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6)
Hypopigmented malignant melanoma in a patient with oculocutaneous albinism type 4
- 23 February 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (2) , e13221
Synonymous but Significant: New Findings of Pathological Variants in Hermansky–Pudlak Syndrome
Hermansky–Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism and systemic complications, including bleeding tendencies. While 11 genes associated with HPS have been identified, cases of HPS5 remain exceedingly rare, particularly in Japan. Here, we report two Japanese patients with novel pathological HPS5 variants, expanding the genetic spectrum of this disorder. Both patients exhibited typical features of mild skin and hair hypopigmentation, and significant ocular involvement. Genetic analysis revealed a heterozygous nonsense variant, NG_008877.1 (NM_181507.2): c.2275G>T, in both patients, inherited from their fathers. Additionally, maternal variants NG_008877.1 (NM_181507.2): c.2952‐13G>A and NG_008877.1 (NM_181507.2): c.1128A>G were identified in patient 1 and patient 2, respectively. These variants, initially presumed non‐pathogenic, were found to induce alternative splicing, leading to truncated protein production. Our findings highlight the functional importance of synonymous variants and their potential role in HPS. This report represents the first documented case of a synonymous pathogenic variant associated with HPS and underscores the need for comprehensive genetic and transcriptomic analyses in rare genetic disorders.
- 23 February 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (2) , e13221
Synonymous but Significant: New Findings of Pathological Variants in Hermansky–Pudlak Syndrome
Hermansky–Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism and systemic complications, including bleeding tendencies. While 11 genes associated with HPS have been identified, cases of HPS5 remain exceedingly rare, particularly in Japan. Here, we report two Japanese patients with novel pathological HPS5 variants, expanding the genetic spectrum of this disorder. Both patients exhibited typical features of mild skin and hair hypopigmentation, and significant ocular involvement. Genetic analysis revealed a heterozygous nonsense variant, NG_008877.1 (NM_181507.2): c.2275G>T, in both patients, inherited from their fathers. Additionally, maternal variants NG_008877.1 (NM_181507.2): c.2952‐13G>A and NG_008877.1 (NM_181507.2): c.1128A>G were identified in patient 1 and patient 2, respectively. These variants, initially presumed non‐pathogenic, were found to induce alternative splicing, leading to truncated protein production. Our findings highlight the functional importance of synonymous variants and their potential role in HPS. This report represents the first documented case of a synonymous pathogenic variant associated with HPS and underscores the need for comprehensive genetic and transcriptomic analyses in rare genetic disorders.